Redeye comments on the positive phase I results for IRL757 announced by IRLAB. We are encouraged to learn that the study confirmed strong safety, tolerability, and pharmacokinetic properties, supporting progression to a fully funded phase Ib trial in apathy patients later this year. We believe that this represents an important milestone in the development of IRL757.
LÄS MER
